Articles
-
Jun 24, 2024 |
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 |
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Jun 24, 2024 |
arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more
The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).
-
Aug 18, 2023 |
amjmed.com | Pamela M Rist |Julie E Buring |JoAnn E. Manson |Joann Manson |Howard D. Sesso
Abstract Although studies have reported migraine and headache as common symptoms of COVID-19, little is known about the association between migraine and risk of developing COVID-19. Prospective cohort study among 16,492 women enrolled in the Women's Health Study who completed a series of questionnaires in 2020 and 2021 concerning the COVID-19 pandemic.
-
Feb 28, 2023 |
inkl.com | Pamela M Rist
The study, which followed women for two decades, has not been published in a peer-reviewed journal and will be presented at the American Academy of Neurology’s annual meeting in Boston. Pamela Rist, an assistant professor and from Brigham and Women’s Hospital in Boston, said: “Since we now know that dementia can begin in the brain decades before diagnosis, it’s important that we learn more about how your habits in middle-age can affect your risk of dementia in old age.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →